PF-Atlas › Clinical Trials › NCT05964335

Cough Reduction in IPF With Nalbuphine ER

NAL ER · Phase 2

Registry ID
NCT05964335
Phase
Phase 2
Status
Completed
Drug / intervention
NAL ER
Sponsor
Trevi Therapeutics
Start
2024-02-06
Enrollment
165
Locations
59

About this trial

The main purpose of the study is to evaluate the effect of NAL ER on 24-hour cough frequency using objective digital cough monitoring and to assess safety and tolerability of NAL ER.

View NCT05964335 on ClinicalTrials.gov →

Explore related

All NAL ER trialsAll IPF trials

Related trials

NAL ER — NCT04030026NAL ER — NCT07671911NAL ER — NCT07036029
Medical disclaimer. This page summarizes public trial data for NCT05964335 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.